Once-daily oral zasocitinib for moderate to severe plaque psoriasis demonstrated rapid and durable skin clearance and a ...
Litifilimab was superior to placebo for reducing skin disease activity in cutaneous lupus erythematosus, according to phase 2 ...
This morning, experts delivered "short and sweet" updates on treatment strategies for common dermatologic conditions. This content was developed independently and is not endorsed by the American ...
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the ...
Research presented at the 2026 AAD Annual Meeting examined patterns of skin cancer prevalence in adults aged 50 years and ...
Program design spans eight educational tracks and more than 275 sessions, underscoring continued expansion of dermatology ...
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 ...
At the American Academy of Dermatology 2026 meeting, dermatology leaders emphasized the growing need for advocacy to address rural access disparities and the escalating impact of climate change on ...
Dermatology may not be a specialty traditionally associated with high costs, but that is changing, in part because of the rise of new biologic drugs. Specialty medications are rapidly driving up ...
RALEIGH, N.C., Mar. 5, 2026 / PRZen / Board-certified dermatologist Sheel Desai Solomon, MD, FAAD, and her practice, ...
Dermatology Physician Assistant Ashley Tanner said the region is a hot spot for allergies that often show up on the skin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results